Comparison
BPC-157 vs TB-500
The two most popular healing peptides compared. They target different mechanisms — and most people use them together. Here's why.
The Short Answer
BPC-157 promotes blood vessel formation at injury sites. TB-500 promotes cell migration to injury sites. Different pathways, same goal. Most healing protocols use both.
| BPC-157 | TB-500 | |
|---|---|---|
| Full name | Body Protection Compound-157 | Thymosin Beta-4 fragment (17-23) |
| Class | Gastric pentadecapeptide | Actin-sequestering peptide fragment |
| Primary mechanism | Angiogenesis (VEGF upregulation) | Cell migration (actin regulation) |
| Amino acids | 15 | 7 (active region of 43-aa parent) |
| Oral viability | Yes — stable in gastric juice | No — injection only |
| Administration | SubQ injection or oral | SubQ injection |
| Typical dose | 250–500 mcg 1–2x daily | 2–5 mg 2–3x per week |
| Half-life | ~1–2 hours | ~2–4 hours |
| Research volume | 100+ preclinical studies | Extensive (parent protein Tβ4) |
| Human trials | None completed | RGN-259 (eye drops) Phase II/III |
| FDA status | Not approved | Not approved (RGN-259 investigational) |
| Key strength | Gut healing, tendon repair, oral dosing | Systemic healing, cardiac repair, flexibility |
| Best for | Localized injuries, GI healing | Systemic recovery, large tissue areas |
When to Use BPC-157
Choose BPC-157 when dealing with localized injuries — tendon tears, muscle strains, ligament damage, joint issues. Its angiogenic mechanism brings blood supply directly to the injury site. Also the clear choice for any gut-related issue (IBS, ulcers, gut permeability) since it's stable in gastric juice and can be taken orally.
When to Use TB-500
Choose TB-500 for systemic recovery, large-area injuries, or conditions requiring broad tissue remodeling. Its actin-regulation mechanism promotes cell migration throughout the body. TB-500 is also researched for cardiac repair and has anti-fibrotic properties that BPC-157 doesn't share.
When to Use Both
Most healing protocols combine them because they target complementary pathways. BPC-157 creates new blood vessels at the injury site (supply) while TB-500 drives cells to migrate there (demand). The combination covers both sides of the healing equation. Typical protocol: BPC-157 250–500 mcg daily + TB-500 2–5 mg twice weekly, for 4–6 weeks.